LRP3-S1 inhibited the MAPK and FAK/AKT/GSK-3 signaling pathways in pancreatic cancer cell lines BxPC-3, PANC-1, and AsPC-1. This evidence concerns the gene AKT1 and pancreatic neoplasm.